Clinical trial

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

NCT04772287

Study summary

ClinicalTrials.gov

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Toripalimab Normalized identity: toripalimab View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Toripalimab mimetic (placebo) Find medicine records · Find other trials using this name

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2021-03-31

PhasePHASE3

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

ToripalimabDRUG · verified · RxNorm: toripalimab

Toripalimab mimetic (placebo)DRUG

Sponsors & collaborators

Shanghai Pulmonary Hospital, Shanghai, Chinalead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04772287 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.